

## CURRICULUM VITAE ENGLISH

### 1. Personal Data

Complete name: KARINA COSTA MAIA VIANNA	Year of Birth: 1975
E-mail: kcmvianna@yahoo.com.br	Telephone: +55 41 3024-2421

### 2. Academic Title

Full title or abbreviation: M.D.
----------------------------------

### 3. Present position with full work address

Position: Principal Investigator	Street address or postal address: Rua: Desembargador Vieira Cavalcanti, 1152
Name of institution or organization: Centro Integrado de Oncologia de Curitiba	City & postal/zip code: Curitiba, Paraná - 80810-050
Start date: December/2008	Country: Brazil

### 4. Main university degree(s)

Name of university/institute: Universidade Federal do Paraná	Degree awarded: MD
City & country: Curitiba – Brazil	Year of graduation: 1999

### 5. Postgraduate education/specialization/training

Name of university/institute: Universidade Federal do Paraná	City & country: Curitiba – Brazil
Qualification: Residence in Clinical Medicine	Dates of attendance: 2000 – 2002
Name of university/institute: Universidade Federal do Paraná	City & country: Curitiba – Brazil
Qualification: Residence in Clinical Oncology	Dates of attendance: 2002 - 2004
Name of university/institute: Universidade Federal do Paraná	City & country: Curitiba – Brazil
Qualification: Master's in Medicina Interna	Dates of attendance: 2008 - 2011

### 6. Registration number/medical license number (where applicable)

CRM/PR: 17.900
----------------

## 7. Complementary Education

- International Fellow Ship - Hospital St Jude Children's Research, SJCRH, EUA 2003;
- Title of Specialist in Oncology, Brazilian Society of Oncology 2005;
- Rave EDC Essentials for Clinical Research Coordinators; Rave Report – Medidata University, 2016;
- ePIP Site User Training Confirmation – Bristol-Myers Squibb CA209-169, 2016;
- GCP IHC E6 for site personal investigator, TransCelerate BioPharma 2015 and 2016;
- CA209-651 / CA209-714 Investigators Meeting – Bristol-Myers Squibb CA209-169; 2017;
- 2017 ASCO Meeting. 2017;
- JPCF-MonarchE – Investigators Meeting – Eli Lilly, 2017;
- CA209-9KD –CheckMate - Investigators Meeting – Bristol Myers Squibb, 2018;
- GCP IHC E6 for site personal investigator, TransCelerate BioPharma, 2019.

## 8. Previous appointments

Position: Technical direct	Dates: December 2008 to Until now
Name of institution or organization: Centro Integrado de Oncologia de Curitiba	City & country: Curitiba - Brazil
Position: Technical direct	Dates: 2006 to Until now
Name of institution or organization: Hospital de Clínicas de Curitiba - HC/UFPR	City & country: Curitiba - Brazil
Position: Preceptor	Dates: 2004 to Until now
Name of institution or organization: Hospital de Clínicas de Curitiba – HC/UFPR	City & country: Curitiba - Brazil

## 9. Clinical research experience (append publication list if available)

- A double-blind, randomized, two arm Phase 2 study of Nivolumab in combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo in recurrent or metastatic squamous cell carcinoma of the head and neck (CA209-714);
- An open label, single arm, multicenter, safety study of Atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract (SAUL);
- Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (CASSINI);
- A randomized, open-label, phase 3 study of Abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptor positive, human epidermal receptor 2 negative, breast cancer (MONARCHE);
- A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CA209-9KD);
- A randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA);
- A randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer (PROPEL);
- A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-line Durvalumab in Combination with Standart of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standart of Care Chemotherapy Versus Standart of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE);
- A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm<sup>+</sup> and MET<sup>+</sup>, Locally



Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib (SAVANNAH);


- A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX);
- A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer (MAGNITUDE);
- Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (PREVALENCE);
- A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811);
- A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma (MK3475-859);
- A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937);
- A Phase III, Open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in Patients with locally advanced, unresectable stage III non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation (SKYSCRAPER-03).

#### 10. Other activities pertinent to professional qualification

- Language – English  
Toefel - Examinee's Score Record

### 11. Peer- Reviewed Published Articles:

1. VIANNA, K. C. M.; sergio padilha; José Zanis Neto; Bianca Ferronato; Felipe de Almeida; Lucas Uratani. Stromal Tumor Gastrointestinal: Experience in the Treatment of Disease and Advanced Located at the Clinical Hospital of the Federal University of Parana. Brazilian Journal of Oncology. v.48, p.47 - 56, 2012.
2. Cícero de Andrade Urban; VIANNA, K. C. M. Attitudes and barriers in prescribing morphine gynecologists. Journal of the Brazilian Society of Oncology., v.11, p.27 - 34, 2000.

Signature:	Date:
	08/ Feb / 2021